Anti-rabies monoclonal antibody - Molecular Targeting Technologies/North China Pharmaceutical CorporationAlternative Names: Human anti-rabies mAb; NM-57; SO-57; SOJB
Latest Information Update: 16 Oct 2015
At a glance
- Originator Thomas Jefferson University
- Developer Molecular Targeting Technologies; North China Pharmaceutical Corporation
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Rabies
Most Recent Events
- 16 Oct 2015 Phase-II clinical trials in Rabies in China (IM) before October 2015